kdrl Antibody – Rabbit Polyclonal

Embryonic vascular system undergoes a series of complex, highly regulated series of events involving differentiation, migration and association of primitive endothelial cells. This process is termed vasculogenesis. A further remodeling of the primitive vascular system forms the mature cardiovascular system. This process is known as angiogenesis (sprouting of new capillary vessels from pre-existing vasculature). Study of tumor angiogenesis has led to the identification of several proteins including basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF). VEGF acts by interacting with a family of largely endothelial-specific receptor tyrosine kinases that includes VEGFR-1 (flt-1 or fms-like tyrosine kinase 1), VEGFR-2 (flk-1 or fetal liver kinase-1/KDR or Kinase insert domain containing receptor), and VEGFR-3/Flt-4. Disruption of VEGFRs interferes with differentiation of endothelial cells and it is lethal for the embryo.

Small volumes of anti-kdrl antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS630950 is an antibody targeting kdrl. Also known as Anti-FLK1 (Vascular Endothelial Growth Factor Receptor 2, VEGFR-2, Fetal Liver Kinase 1, FLK-1, Kinase NYK, Protein-tyrosine Kinase Receptor flk-1, CD309, Kdr, Flk-1, Flk1). Reactive in Human; Mouse; Rat. Host: Rabbit.